Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
=== Pakistan === The 2012 Pakistan fake medicine crisis revealed the scale of production of counterfeit medications in Pakistan. Over 100 heart patients died after administration of adulterated drugs by the Punjab Institute of Cardiology. Pakistan did not have any regulatory enforcement on production of medicines until this crisis occurred. In response to the crisis, a regulatory body was finally set up in February 2012.
=== Neonicotinoids === Neonicotinoids are a class of neuro-active insecticides chemically similar to nicotine, with much lower acute mammalian toxicity and greater field persistence. These chemicals are acetylcholine receptor agonists. They are broad-spectrum systemic insecticides, with rapid action (measured in minutes or hours). They are applied as sprays, drenches, seed and soil treatments. Treated insects exhibit leg tremors, rapid wing motion, stylet withdrawal (aphids), disoriented movement, paralysis and death. Imidacloprid, of the neonicotinoid family, is the most widely used insecticide in the world. In the late 1990s neonicotinoids came under increasing scrutiny over their environmental impact and were linked in a range of studies to adverse ecological effects, including honey-bee colony collapse disorder (CCD) and loss of birds due to a reduction in insect populations. In 2013, the European Union and a few non EU countries restricted the use of certain neonicotinoids. and its potential to increase the susceptibility of rice to planthopper attacks.
=== Elected officials === Mayor: Matthew Gentry Clerk-Treasurer: Tonya Thayer City Council, District 1: Mike Kincaid City Council, District 2: Keith Campbell City Council, District 3: Sandra Jasionowski City Council, District 4: Dick Robertson City Council, District 5: John Copeland City Council, At Large: Sierra Messenger City Council, At Large: Robert Hawkins
Sources: en.wikipedia.org
== NFL career == The Washington Redskins signed him on August 15, 2015. This came on the back of Niles Paul and Logan Paulson being placed on the Injured Reserve list. He was waived on August 31, 2015.
==== 1100–1199 ==== Welfare Food Amendment Regulations 1993 (S.I. 1993/1105) A630 Trunk Road (Rotherham) (Detrunking) Order 1993 (S.I. 1993/1107) Social Security (Claims and Payments) Amendment (No. 2) Regulations 1993 (S.I. 1993/1113) Local Fisheries Committees (Fees for Copy Byelaws) Order 1993 (S.I. 1993/1116) Legal Aid in Family Proceedings (Remuneration) (Amendment) Regulations 1993 (S.I. 1993/1117) Central and Fife Regions and Clackmannan and Dunfermline Districts (River Forth, Kilbagie Mill, Slack Cottage and River Black Devon) Boundaries Amendment Order 1993 (S.I. 1993/1118) Transport and Works Applications (Inland Waterways Procedure) Regulations 1993 (S.I. 1993/1119) Local Government Finance (Housing) (Consequential Amendments) (Amendment) Order 1993 (S.I. 1993/1120) Road Traffic (Training of Drivers of Vehicles Carrying Dangerous Goods) (Amendment) Regulations 1993 (S.I. 1993/1122) Value Added Tax (Education) (No. 2) Order 1993 (S.I. 1993/1124) Grampian Region (Electoral Arrangements) Order 1993 (S.I. 1993/1125) Moray Health Services National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1126) Royal Scottish National Hospital and Community National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1127) Royal Alexandra Hospital National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1128) Raigmore Hospital National Health Service Trust (Appointment of Trustees) Order 1993 (S.I. 1993/1129) Grampian Healthcare National Health Service Trust (Appointment of Trustees) Order 1993 (S.I.
Animal studies indicate the amatoxins deplete hepatic glutathione; N-acetylcysteine serves as a glutathione precursor and may therefore prevent reduced glutathione levels and subsequent liver damage. None of the antidotes used have undergone prospective, randomized clinical trials, and only anecdotal support is available. Silibinin and N-acetylcysteine appear to be the therapies with the most potential benefit. Repeated doses of activated carbon may be helpful by absorbing any toxins that are returned to the gastrointestinal tract following enterohepatic circulation. Other methods of enhancing the elimination of the toxins have been trialed; techniques such as hemodialysis, hemoperfusion, plasmapheresis, and peritoneal dialysis have occasionally yielded success but overall do not appear to improve outcome. In patients developing liver failure, a liver transplant is often the only option to prevent death. Liver transplants have become a well-established option in amatoxin poisoning. This is a complicated issue, however, as transplants themselves may have significant complications and mortality; patients require long-term immunosuppression to maintain the transplant. That being the case, there has been a reassessment of criteria such as onset of symptoms, prothrombin time (PTT), serum bilirubin, and presence of encephalopathy for determining at what point a transplant becomes necessary for survival.
Sources: en.wikipedia.org
==== Actions ==== Compound 22 is a low-potency antagonist of the trace amine-associated receptor 1 (TAAR1). It has shown significant inhibition of TAAR1 signaling at a concentration of 100 μM in vitro. The drug's IC50Tooltip half-maximal inhibitory concentration value for TAAR1 antagonism is unknown but is greater than 100 μM. Compound 22 was also screened for off-target activity at 47 targets at a concentration of 10 μM. The screened targets included monoamine receptors, monoamine transporters, histamine receptors, muscarinic acetylcholine receptors, glutamate receptors, GABA receptors, opioid receptors, and sigma receptors. There were five hits (>50% binding inhibition), which included the serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET), as well as the sigma σ1 and σ2 receptors. Its affinities (Ki) were 1,800 nM for the SERT, 1,053 nM for the DAT, 1,902 nM for the NET, 276 nM for the sigma σ1 receptor, and 412 nM for the sigma σ2 receptor. Although compound 22 bound with significant affinity to the DAT, it did not inhibit dopamine reuptake and did not interfere with cocaine-induced dopamine reuptake inhibition at concentrations of up to 100 μM.
In 2009, 86% of cadmium was used in batteries, predominantly in rechargeable nickel–cadmium batteries. Nickel–cadmium cells have a nominal cell potential of 1.2 V. The cell consists of a positive nickel hydroxide electrode and a negative cadmium electrode plate separated by an alkaline electrolyte (potassium hydroxide). The European Union put a limit on cadmium in electronics in 2004 of 0.01%, with some exceptions, and in 2006 reduced the limit on cadmium content to 0.002%. Another type of battery based on cadmium is the silver–cadmium battery.
== Dried plasma spot == This technology is similar to dried blood spot sampling however instead of collecting whole blood on a membrane, it separates red blood cells from plasma. A dried plasma spot (DPS) is usually a drop of capillary blood on a plasma separation card, the first membrane will filter all the red blood cells, while the second membrane aborbs the cell free plasma. This method is ideal for processing and storage of plasma.
Incandescent lamps are very sensitive to changes in the supply voltage. These characteristics are of great practical and economic importance. For a supply voltage V near the rated voltage of the lamp:
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.